Q3 FY2026 · ended Sep 30, 2026 · Revenue $3.81B, +6.9% YoY · Filed Oct 30, 2026
Labcorp Holdings Inc. (LH) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $3.8 billion and net income of $262.8 million. Free cash flow was $412.2 million. As of Sep 30, 2026 it held $261.8 million in cash and investments and $6.8 billion in total debt.
Revenue
$3.81B
+6.9% vs year-ago quarter
Net income
$262.80M
+0.7% vs year-ago quarter
Operating cash flow
$563.80M
+45.6% vs year-ago quarter
Free cash flow
$412.20M
+47.0% vs year-ago quarter
EPS
$3.22
+3.2% vs year-ago quarter
Dividend per share
$0.72
+0.0% vs year-ago quarter
Shares outstanding
81.20M
-2.1% vs year-ago quarter
Net cash
$-6.51B
Q3 FY2026
Operating margin
10.3%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- LH (NYSE)
- Fiscal year ends
- December 31
- Headquarters
- Burlington, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 920148
- Former names
- LABORATORY CORP OF AMERICA HOLDINGS (until May 16, 2024); NATIONAL HEALTH LABORATORIES HOLDINGS INC (until Feb 13, 1995)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.7B | $3.5B | $3.5B | $3.6B |
| Operating income | $402.1M | $451.6M | $380.8M | $267.6M | $396.6M |
| Net income | $262.8M | $298.7M | $277.8M | $164.7M | $261.1M |
| Diluted EPS | $3.22 | $3.64 | $3.35 | $1.98 | $3.12 |
| Operating cash flow | $563.8M | $445.5M | $191.5M | $614.2M | $387.2M |
| Free cash flow | $412.2M | $313.9M | $70.5M | $490.3M | $280.5M |
| Total assets | $18.9B | $18.5B | $19.1B | $18.4B | $18.3B |
| Total liabilities | $10.1B | $9.9B | $10.3B | $9.8B | $9.5B |
| Stockholders' equity | $8.8B | $8.6B | $8.7B | $8.6B | $8.7B |
| Cash and investments | $261.8M | $141.8M | $981.1M | $532.3M | $598.1M |
| Total debt | $6.8B | $6.8B | $7.2B | $6.5B | $6.0B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
All 1002 Labcorp Holdings Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.